SPOP and nonpapillary renal cell carcinoma: Previous studies have validated SPOP as an attractive target for the treatment of clear-cell renal cell carcinoma (ccRCC) and reported the first SPOP inhibitor, but it is a challenging target in terms of protein–protein interactions46.